Pediatrix Medical vs Surgery Partners
MD and SGRY side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How MD and SGRY compare
Surgery Partners is the larger company, worth 1.3 times as much as Pediatrix Medical ($3.0B against $2.4B).
Surgery Partners grew revenue faster over the last twelve months (4.0% versus 1.9% for Pediatrix Medical).
Pediatrix Medical keeps more of each dollar of sales as profit, with a net margin of 7.7% compared with −2.6% at Surgery Partners.
Pediatrix Medical scores higher on the StockData Score (10 against 6 for Surgery Partners), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | MD | SGRY |
|---|---|---|
| Size and price | ||
| Market cap | $2.4B | $3.0B |
| Share price | $29.82 | $23.21 |
| Change, 1 year | 66.9% | 2.0% |
| Change, 5 years | 4.0% | −53.7% |
| Beta (5Y) | 0.69 | 1.64 |
| Employees | – | 16K |
| StockData Score | ||
| Total score | 10 (better) | 6 |
| Valuation score | 2 | 2 |
| Growth score | 1 (better) | 0 |
| Performance score | 4 (better) | 2 |
| Health score | 3 (better) | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 16.2× | – |
| P/S | 1.2× | 0.9× (better) |
| P/B | 2.9× | 1.8× (better) |
| EV/EBITDA | 10.9× (better) | 14.3× |
| P/FCF | – | 16.2× |
| PEG | 0.46 | – |
| FCF yield | – | 6.2% |
| Fair value | $28.35 | $21.97 |
| Margin of safety | −5.2% (better) | −5.7% |
| Growth | ||
| Revenue growth (TTM) | 1.9% | 4.0% (better) |
| Revenue growth, 5Y average | 2.0% | 12.2% (better) |
| Net income growth (TTM) | −7.5% | – |
| EPS growth (TTM) | −3.2% | – |
| Profitability | ||
| Operating margin | 10.9% | 11.4% (better) |
| Net margin | 7.7% (better) | −2.6% |
| FCF margin | – | 5.6% |
| Return on equity | 17.2% (better) | −5.2% |
| Return on invested capital | 15.4% (better) | 5.9% |
| Financial health | ||
| Debt / equity | 0.68 (better) | 2.25 |
| Net debt / EBITDA | 0.64 (better) | 6.30 |
| Interest coverage | 6.4× | – |
| Current ratio | 1.28 | 1.95 (better) |
| Altman Z-score | 2.45 (better) | 0.87 |
| Piotroski F-score | 6 (better) | 4 |
| Dividends and buybacks | ||
| Buyback yield | 8.6% | – |
| Shareholder yield | 8.6% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 103% | 121% |
| Held by insiders | 1.4% | 85.9% |
| Insider net buying, 12 months | −$1.8M | −$979K (better) |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 5.8% | 77.9% |
Go deeper
- MD stock overview
- MD income statement
- MD valuation and score
- SGRY stock overview
- SGRY income statement
- SGRY valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.